MedTrace Logo

Paracetamol Toxicity in Septic Patients

NCT01182974 · Status: SUSPENDED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2011-03-02

No results posted yet for this study

Summary

The investigators will examine the toxicity of therapeutic doses of paracetamol in patients in severe sepsis. Patients with fever and severe sepsis will be randomized to receive paracetamol or dypirone. The investigators will monitor blood glutathione and liver enzymes to look for potential toxicity.

Conditions

Interventions

DRUG

paracetamol

1 gr of paracetamol PO/PZ/PR

DRUG

dypirone

1 gr PO/PZ/PR/IM

Sponsors & Collaborators

  • Hadassah Medical Organization

    collaborator OTHER

  • Barzilai Medical Center

    lead OTHER

Principal Investigators

  • Albert Grinshpun · Barziali medical center, Ashkelon

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2011-08-31
Completion
2011-08-31

Countries

  • Israel

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01182974 on ClinicalTrials.gov